WO2009024359A1 - Agents de traitement capillaire contenant une ou plusieurs substances de soin et mélatonine/agomélatine - Google Patents

Agents de traitement capillaire contenant une ou plusieurs substances de soin et mélatonine/agomélatine Download PDF

Info

Publication number
WO2009024359A1
WO2009024359A1 PCT/EP2008/053226 EP2008053226W WO2009024359A1 WO 2009024359 A1 WO2009024359 A1 WO 2009024359A1 EP 2008053226 W EP2008053226 W EP 2008053226W WO 2009024359 A1 WO2009024359 A1 WO 2009024359A1
Authority
WO
WIPO (PCT)
Prior art keywords
weight
hair
mono
acid
branched
Prior art date
Application number
PCT/EP2008/053226
Other languages
German (de)
English (en)
Inventor
Erik Schulze Zur Wiesche
Elisabeth Poppe
Original Assignee
Henkel Ag & Co. Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henkel Ag & Co. Kgaa filed Critical Henkel Ag & Co. Kgaa
Publication of WO2009024359A1 publication Critical patent/WO2009024359A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A61K8/355—Quinones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A61K8/416—Quaternary ammonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/12—Preparations containing hair conditioners

Definitions

  • the present invention relates to hair treatment compositions containing care substance (s), fatty substances) as well as a combination of active ingredients of melatonin and / or agomelatine and at least one care enhancer.
  • Human hair is today treated in a variety of ways with hair cosmetic preparations. These include, for example, the cleansing of hair with shampoos, the care and regeneration with rinses and cures and the bleaching, dyeing and shaping of the hair with dyes, tinting agents, waving agents and styling preparations.
  • the hair is treated with special active ingredients, for example quaternary ammonium salts or special polymers, usually in the form of a rinse.
  • special active ingredients for example quaternary ammonium salts or special polymers, usually in the form of a rinse.
  • this treatment improves the combability, the hold and the fullness of the hair and reduces the splitting rate.
  • a keratin-containing fiber coloring agent should not only provide excellent coloration as a key parameter, but should also ensure that the fibers are easy to handle, maintain, protect from environmental influences after dyeing, and be consolidated in the fiber structure.
  • Cosmetic agents that simultaneously target various parameters of the substrate are generally referred to in this application as a "2-in-1 product.” By using a 2-in-1 product, the user saves the annoying multiple applications of a variety of cosmetic products.
  • the permanent, oxidative staining as well as the hair bleaching and fixation in the context of perm usually take place as an oxidative hair treatment in the presence of oxidizing agents, such as hydrogen peroxide.
  • oxidizing agents such as hydrogen peroxide.
  • the oxidizing agent not only achieves the desired cosmetic effect, but also has a negative effect on the stability, the feel and the appearance of the keratin-containing fiber, in particular the human hair. Such damaged hair looks dull and brittle. In extreme cases, it even leads to hair breakage.
  • the convenience of the consumer tends to be overcome by the use of a 2-in-1 product for subsequent applications to conceal the aforementioned undesirable effects.
  • active ingredients both for separate aftertreatment agents and for combination preparations generally have a preferential effect on the hair surface.
  • active ingredients are known which give the hair shine, hold, fullness, better wet or dry combabilities or prevent splitting.
  • the internal structural cohesion of the hair fibers which can be greatly influenced, in particular, by oxidative and reductive processes such as dyeing and perming.
  • the known active ingredients can not cover all needs sufficiently. There is therefore still a need for active ingredients or combinations of active substances for cosmetic products with good care properties and good biodegradability. Especially in dye-containing and / or electrolyte-containing formulations, there is a need for additional nourishing active ingredients which can be easily incorporated into known formulations and are not weakened in their action due to incompatibilities with other ingredients. It is an object of the present invention to provide hair treatment compositions which impart advantageous properties to the hairs treated with them. In particular, damage from external influences and from aging should be reduced and / or avoided.
  • the main task was to provide means that the vitalization of hair and / or the stimulation of energy metabolism in hair follicles and / or the activation of hair follicles and / or the promotion or enhancement of hair growth and / or hair thickening and / or the treatment of hair loss and / or to influence (in particular excitation) the keratin synthesis.
  • the tensile strength of keratinic fibers, in particular human hair should be improved and the moisture balance of keratinic fibers, in particular human hair, stabilized. This should allow further improvements, in particular combability, as well as the improvement of the ability to restructure and the reduction in the elasticity of keratinic fibers, in particular human hair.
  • conditioning hair treatment compositions which achieve the stated objects if they contain at least one cationic care substance, at least one fatty component and a combination of active ingredients of melatonin and / or agomelatine and at least one particular care enhancer.
  • the present invention is in a first embodiment, a hair treatment agent containing
  • At least one care enhancer from group i. L-carnitine and / or its salts; ii. Panthenol and / or panthothenic acid; iii. the 2-furanones and / or their derivatives, in particular pantolactone; iv. Taurine and / or its salts; v. niacinamide; vi. Ubiquinone vii. Ectoin; viii. allantoin; ix. Extracts of Echinacea.
  • compositions according to the invention contain at least one cationic care substance. This is preferably selected from cationic surfactants and cationic polymers.
  • Cationic surfactants of the quaternary ammonium compounds, esterquats and amidoamines type are preferably usable according to the invention.
  • Preferred quaternary ammonium compounds are ammonium halides, in particular chlorides and bromides, such as alkyltrimethylammonium chlorides, dialkyldimethylammonium chlorides and trialkylmethylammonium chlorides.
  • the long alkyl chains of these surfactants preferably have 10 to 18 carbon atoms, such as.
  • cetyl trimethyl ammonium chloride stearyl trimethyl ammonium chloride, distearyl dimethyl ammonium chloride, lauryl dimethyl ammonium chloride, lauryl dimethyl benzyl ammonium chloride and tricetylmethyl ammonium chloride.
  • Further preferred cationic surfactants are the imidazolium compounds known under the INCI names Quaternium-27 and Quaternium-83.
  • Particularly preferred hair treatment compositions according to the invention are characterized in that they contain as cationic care substance - based on their weight - 0.05 to 7.5 wt .-%, preferably 0.1 to 5 wt .-%, particularly preferably 0.2 to 3, 5 wt .-% and in particular 0.25 to 2.5 wt .-% cationic (s) surfactant (s) from the group of quaternary ammonium compounds and / or the esterquats and / or the amidoamines containing preferred cationic (s) Surfactant (s) is / are selected
  • Alkyltrimethylammoniumchloriden having preferably 10 to 18 carbon atoms in the alkyl radical and / or
  • Dialkyldimethylammoniumchloride having preferably 10 to 18 carbon atoms in the alkyl radical and / or
  • Trialkylmethylammoniumchloride having preferably 10 to 18 carbon atoms in the alkyl radical and / or
  • Tricetylmethylammonium chloride quaternium-27 and / or - Quaternium-83 and / or
  • N N-dimethyl-N, N-distearoyloxyethyl ammonium chloride and / or N, N-di (2-hydroxyethyl) -N, N- (fatty acid ethyl) ammonium chloride.
  • the agents according to the invention may also contain nonionic and optionally also amphoteric or zwitterionic surfactants.
  • Nonionic surfactants and emulsifiers contain as hydrophilic group z.
  • Such compounds are, for example
  • Polyol fatty (partial) ester as Hydagen ® HSP (Cognis) or Sovermol ® - types (Cognis), especially of saturated C 8 - 3 o-fatty acids, alkoxylated triglycerides, alkoxylated fatty acid alkyl esters,
  • Sugar and x represents the number of sugar units.
  • R consists essentially of C 8 and C 10 -alkyl groups, essentially of C 12 and C 14 -alkyl groups, essentially of C 8 to C 16 -alkyl groups or essentially of C 12 - to C 16 -alkyl groups or consisting essentially of C 16 to C 18 alkyl groups.
  • sugar building block Z it is possible to use any desired mono- or oligosaccharides.
  • sugars with 5 or 6 carbon atoms and the corresponding oligosaccharides are used.
  • Such sugars are, for example, glucose, fructose, galactose, arabinose, ribose, xylose, lyxose, allose, altrose, mannose, gulose, idose, talose and sucrose.
  • Preferred sugar building blocks are glucose, fructose, galactose, arabinose and sucrose; Glucose is particularly preferred.
  • alkylpolyglycosides which can be used according to the invention contain on average 1, 1 to 5 sugar units. Alkyl polyglycosides having x values of 1.1 to 2.0 are preferred. Very particular preference is given to alkyl glycosides in which x is 1: 1 to 1, 8.
  • alkyl (oligo) glucosides eg. B. Montanov ® 68
  • fatty alcohols eg. B. Montanov ® 68
  • Sterols e.g. Ergosterol, stigmasterol, sitosterol and mycosterols,
  • Phospholipids e.g. B. lecithins or phosphatidylcholines
  • Polyglycerols and polyglycerol derivatives such as polyglycerol poly-12-hydroxystearate
  • Preferred nonionic surface-active substances have been the alkylpolyglycosides, optionally in admixture with fatty alcohols, alkoxylated polydialkylsiloxanes, alkylene oxide amide products of saturated linear fatty alcohols and fatty acids with 2 to 30 moles of ethylene oxide per mole of fatty alcohol or fatty acid.
  • Zwitterionic surfactants and emulsifiers are surface-active compounds which contain in the molecule at least one quaternary ammonium group and at least one - wear or -SO '' 'group 3
  • Particularly suitable zwitterionic surfactants and emulsifiers are the so-called betaines such as the N - COO ().
  • N alkyl N, N-dimethylammonium glycinates, for example cocoalkyldimethylammonium glycinate, N-acylaminopropyl N, N-dimethylammonium glycinates, for example cocoacylaminopropyldimethylammonium glycinate, and 2-alkyl-3-carboxymethyl-3-hydroxyethylimidazolines having in each case 8 to 18 C
  • a preferred zwitterionic surfactant is the fatty acid amide derivative known by the INCI name cocamidopropyl betaine.
  • Ampholytic surfactants and emulsifiers are understood as meaning those surface-active compounds which, apart from a C 8 -C 24 -alkyl or -acyl group, contain at least one free amino group and at least one -COOH or -SO 3 H group and are capable of forming internal salts
  • suitable ampholytic surfactants are N-alkylglycines, N-alkylaminopropionic acids, N-alkylaminobutyric acids, N-alkyliminodipropionic acids, N-hydroxy- ethyl-N-alkylamidopropylglycines, N-alkyltaurines, N-alkylsarcosines, 2-alkylaminopropionic acids and alkylaminoacetic acids each having about 8 to 24 carbon atoms in the alkyl group.
  • Particularly preferred ampholytic surfactants are N-cocoalkylaminopropionate, cocoacylaminoethylaminoprop
  • compositions according to the invention may contain cationic polymers. These can be used together with cationic surfactants or replace them.
  • Cationic polymers in the sense of the present application are polymers which have cationic groups. Depending on whether additionally anionic groups are contained in the polymer, strictly speaking, they are "purely cationic" or amphoteric polymers.
  • Cationic or amphoteric polymers are to be understood as meaning polymers which have a group in the main and / or side chain which may be “temporary” or “permanent” cationic.
  • "permanently cationic” refers to those polymers which have a cationic group, irrespective of the pH of the agent. These are usually polymers containing a quaternary nitrogen atom, for example in the form of an ammonium group.
  • Preferred cationic groups are quaternary ammonium groups.
  • those polymers in which the quaternary ammonium group is bonded via a C 1-4 hydrocarbon group to a polymer main chain constructed from acrylic acid, methacrylic acid or derivatives thereof have proven to be particularly suitable.
  • the agents according to the invention can also contain amphoteric polymers. These additionally have at least one negatively charged group in the molecule and are also referred to as zwitterionic polymers.
  • agents according to the invention are preferred which, based on their weight, are from 0.05 to 7.5% by weight, preferably from 0.1 to 5% by weight, more preferably from 0.2 to 3.5% by weight and in particular from 0.25 to 2.5% by weight of amphoteric polymer (s).
  • agents contain amphoteric polymers or not
  • further preferred agents according to the invention are characterized in that they contain, based on their weight, 0.05 to 7.5% by weight, preferably 0.1 to 5% by weight. -%, particularly preferably 0.2 to 3.5 wt .-% and in particular 0.25 to 2.5 wt .-% cationic (s) polymer (s) included.
  • Cationic polymers which can preferably be used according to the invention are described below: Homopolymers of the general formula (G1-I),
  • R 1 -H or -CH 3
  • R 2 , R 3 and R 4 are independently selected from C 1-4 -alkyl, -alkenyl or -hydroxyalkyl groups
  • m 1, 2, 3 or 4
  • n is a natural number
  • X is a physiologically acceptable organic or inorganic anion
  • copolymers consisting essentially of the monomer units listed in formula (G1-I) and nonionic monomer units are particularly preferred cationic polymers preferably, for which at least one of the following conditions applies:
  • R 1 is a methyl group
  • R 2 , R 3 and R 4 are methyl groups m has the value 2.
  • Suitable physiologically acceptable counterions X ' are, for example, halide ions, sulfate ions, phosphate ions, methosulfate ions and organic ions such as lactate, citrate, tartrate and acetate ions. Preference is given to halide ions, in particular chloride.
  • a particularly suitable homopolymer is the optionally crosslinked, poly (methacryloyloxyethyltrimethylammonium chloride) with the INCI name Polyquaternium 37.
  • Such products are (Cosmetic Rheologies) and Synthalen ® CR (Ethnichem), for example under the names Rheocare ® CTH are commercially available.
  • the crosslinking can be carried out with the aid of poly olefinically unsaturated compounds, for example divinylbenzene, tetraallyloxyethane, methylenebisacrylamide, diallyl ether, polyallylpolyglyceryl ethers, or allyl ethers of sugars or sugar derivatives such as erythritol, pentaerythritol, arabitol, mannitol, sorbitol, sucrose or glucose.
  • Methylenebisacrylamide is a preferred crosslinking agent.
  • the homopolymer is preferably used in the form of a nonaqueous polymer dispersion which should not have a polymer content of less than 30% by weight.
  • Such polymer dispersions are (under the names Salcare ® SC 95 about 50% polymer content, additional components: mineral oil (INCI name: Mineral Oil) and tridecyl-polyoxypropylene-polyoxyethylene-ether (INCI name: PPG-1 trideceth-6) ) and Salcare ® SC 96 (about 50% polymer content, more Components: mixture of diesters of propylene glycol with a mixture of caprylic and capric acid (INCI name: propylene glycol dicaprylate / dicaprate) and tridecyl polyoxypropylene-polyoxyethylene ether (INCI name: PPG-1-trideceth-6)) commercially available.
  • Copolymers with monomer units of the formula (G1-I) contain, as nonionic monomer units, preferably acrylamide, methacrylamide, acrylic acid C-. 4- alkyl esters and methacrylic d- 4- alkyl esters. Among these nonionic monomers, the acrylamide is particularly preferred. These copolymers can also be crosslinked, as described above in the case of the homopolymers. A copolymer preferred according to the invention is the crosslinked acrylamide-methacryloyloxyethyltrimethylammonium chloride copolymer. Such copolymers in which the monomers are present in a weight ratio of about 20:80, are commercially available as approximately 50% non-aqueous polymer dispersion 92 under the name Salcare ® SC.
  • quaternized cellulose derivatives such as are available under the names of Celquat ® and Polymer JR ® commercially.
  • the compounds Celquat ® H 100, Celquat ® L 200 and Polymer JR ® 400 are preferred quaternized cellulose derivatives, cationic alkyl polyglycosides according to DE-PS 44 13 686, cationized honey, for example the commercial product Honeyquat ® 50, cationic guar derivatives, such as in particular the products sold under the trade name Cosmedia guar ® and Jaguar ® products, polymeric dimethyldiallylammonium salts and their copolymers with esters and amides of acrylic acid and methacrylic acid.
  • Such compounds are sold under the names Gafquat ® 734 and Gafquat ® 755 commercially,
  • Vinylpyrrolidone-vinyl imidazolium copolymers such as those offered under the names Luviquat ® FC 370, FC 550, FC 905 and HM 552, quaternized polyvinyl alcohol, as well as by the names of Polyquaternium 2, Polyquaternium 17, Polyquaternium 18 and Polyquaternium 27, having quaternary Nitrogen atoms in the polymer backbone.
  • Can be used as cationic polymers are sold under the names Polyquaternium-24 (commercial product z. B. Quatrisoft ® LM 200), known polymers.
  • Gaffix ® VC 713 manufactured by ISP: Also according to the invention can be used the copolymers of vinylpyrrolidone, such as the commercial products Copolymer 845 (ISP manufacturer) are Gafquat ® ASCP 1011, Gafquat ® HS 110, Luviquat ® 8155 and Luviquat ® MS 370 available are.
  • Cationic protein hydrolysates may also be used as cationic polymers, preferred agents being one or more cationic protein hydrolyzates from the group Cocodimonium Hydroxypropyl Hydrolyzed Collagen, Cocodimonium Hydroxypropyl Hydrolyzed Casein, Cocodimonium Hydroxypropyl Hydrolyzed Collagen, Cocodimonium Hydroxypropyl Hydrolyzed Hair Keratin, Cocodimonium Hydroxypropyl Hydrolyzed Keratin, Cocodimonium Hydroxypropyl Hydrolyzed Rice Protein, Cocodimonium Hydroxypropyl Hydrolyzed Soy Protein, Cocodimonium Hydroxypropyl Hydrolyzed Wheat Protein, Hydroxypropyl Arginine Lauryl / Myristyl Ether HCl, Hydroxypropyltrimonium Gelatin, Hydroxypropyltrimonium Hydrolyzed Casein, Hydroxypropyltrimonium Hydrolyzed Collagen, Hydroxypropyltrimonium Hydrolyzed Con
  • hair treatment compositions according to the invention are preferred which, based on their weight, are from 0.05 to 7.5% by weight, preferably from 0.1 to 5% by weight, particularly preferably from 0.2 to 3.5% by weight, and in particular from 0.25 to 2.5% by weight of cationic polymer (s), preferred cationic polymer (s) being / are selected from
  • Poly (methacryloyloxyethyltrimethylammonium chloride) (INCI: Polyquaternium-37) and / or; quaternized cellulose derivatives (INCI: Polyquaternium 10) and / or cationic alkyl polyglycosides and / or cationised honey and / or cationic guar derivatives and / or polymeric dimethyldiallylammonium salts and their copolymers with esters and amides of acrylic acid and methacrylic acid and / or
  • the agents of the invention may contain amphoteric polymers.
  • amphoteric polymers preferably usable amphoteric polymers are composed essentially together
  • R 1 -CH CR 2 -CO-Z- (C n H 2n ) -N ( + ) R 3 R 4 R 5 A ⁇ " ) ( Z ⁇ ')
  • R 1 and R 2 independently of one another are hydrogen or a methyl group and R, R and R independently represent alkyl groups having 1 to 4 carbon atoms, Z is an NH group or an oxygen atom, n is an integer from 2 to 5 and A ⁇ 'is the anion of an organic or inorganic acid
  • R "and R 7 are independently hydrogen or methyl groups.
  • Suitable starting monomers are, for. Dimethylaminoethylacrylamide,
  • the monomers containing a tertiary amino group are then quaternized in a known manner, methyl chloride, dimethyl sulfate or diethyl sulfate being particularly suitable as alkylating reagents.
  • the quaternization reaction can be carried out in aqueous solution or in the solvent.
  • such monomers of formula (Z-I) will be the derivatives of acrylamide or methacrylamide. Preference is furthermore given to those monomers which contain halide, methoxysulfate or ethoxysulfate ions as counterions. Likewise preferred are those
  • the acrylamidopropyltrimethylammonium chloride is a most preferred monomer of formula (Z-I).
  • Suitable monomeric carboxylic acids of the formula (Z-II) are acrylic acid, methacrylic acid, crotonic acid and 2-methylcrotonic acid. Preference is given to using acrylic or methacrylic acid, in particular acrylic acid.
  • the zwitterionic polymers which can be used according to the invention are prepared from monomers of the formulas (Z-I) and (Z-II) by polymerization processes known per se.
  • the polymerization can be carried out either in aqueous or aqueous-alcoholic solution.
  • the alcohols used are alcohols having 1 to 4 carbon atoms, preferably isopropanol, which simultaneously serve as polymerization regulators.
  • other components than regulators may also be added to the monomer solution, eg.
  • formic acid or mercaptans such as thioethanol and thioglycolic acid.
  • the initiation of the polymerization takes place with the aid of free-radical-forming substances.
  • redox systems and / or thermally decomposing radical formers of the azo compound type such.
  • azoisobutyronitrile azo-bis (cyanopentanoic acid) or azo-bis (amidinopropane) dihydrochloride can be used.
  • redox systems are z. B. combinations of hydrogen peroxide, potassium or ammonium peroxodisulfate and tertiary butyl hydroperoxide with sodium sulfite, sodium dithionite or hydroxylamine hydrochloride as a reduction component.
  • the polymerization can be carried out isothermally or under adiabatic conditions, wherein, depending on the concentration ratios, by the liberated polymerizate.
  • heat of the temperature range for the course of the reaction between 20 and 200 0 C may vary, and the reaction may need to be carried out under the autogenous overpressure.
  • the reaction temperature is between 20 and 100 0 C.
  • the pH during the copolymerization may vary within a wide range.
  • polymerization is carried out at low pH values; however, pH values above the neutral point are also possible.
  • an aqueous base for. As sodium hydroxide, potassium hydroxide or ammonia, to a pH between 5 and 10, preferably 6 to 8 set. Further details of the polymerization process can be found in the examples.
  • amphoteric polymer (s) comprise monomers A) and B), wherein A) and B) are selected from
  • R 1 -CH CR 2 -CO-Z- (C n H 2n ) -N ( + ) R 3 R 4 R 5 A ⁇ " ) ( Z - ') in which R 1 and R 2 independently of one another represent hydrogen or one
  • Methyl group and R, R and R independently of one another are alkyl groups having 1 to 4 carbon atoms, Z is an NH group or an oxygen atom, n is an integer
  • amphoteric polymers used in the agents according to the invention contain monomers from the group of the acrylamides and / or methacrylamides with alkylammonium groups.
  • Acrylic acid and / or methacrylic acid and / or crotonic acid and / or 2-methyl-crotonic acid have proven useful as monomers with anionic groups which are additionally present in the polymers.
  • agents according to the invention are preferred in which the amphoteric polymer (s) are co-polymers of at least one of the monomers
  • Trimethylammoniumpropylacrylamid and / or
  • Trimethylammoniumethylacrylamid and / or
  • amphoteric polymers according to the invention are:
  • compositions according to the invention contain from 0.1 to 10% by weight of one or more fatty components.
  • Hair-treatment compositions according to the invention which additionally comprise fatty substance (s), preferably in amounts of from 0.1 to 20% by weight, more preferably from 0.2 to 15% by weight and in particular from 0.3 to 10% by weight, are preferred. %, in each case based on the total mean.
  • the fatty substances are selected from fatty acids, fatty alcohols, natural and synthetic waxes and natural and synthetic cosmetic oil components.
  • fatty acids (D1) it is possible to use linear and / or branched, saturated and / or unsaturated fatty acids having 6-30 carbon atoms.
  • fatty acids include caproic, caprylic, 2-ethylhexanoic, capric, lauric, isotridecanoic, myristic, palmitic, palmitoleic, stearic, isostearic, oleic, elaidic, petroselic, linoleic, linolenic as well as their technical mixtures, eg occur in the pressure fission of natural fats and oils, in the oxidation of aldehydes from the Rölen's oxo synthesis or the dimerization of unsaturated fatty acids.
  • Particularly preferred are usually the fatty acid cuttings obtainable from coconut oil or palm oil; In particular, the use of stearic acid is usually preferred.
  • the amount used is 0.1-15 wt.%, Based on the total mean.
  • the amount is 0.2-10 wt.%, With very particularly advantageous amounts of 0.5-4 wt .-% are used.
  • fatty alcohols (D2) can be used saturated, mono- or polyunsaturated, branched or unbranched fatty alcohols with C 6 -C 30 -, preferably Ci O -C 22 - and very particularly preferably C ⁇ -C ⁇ carbon atoms.
  • Decanols, octanols, dodecadienol, decadienol, oleyl alcohol, eruca alcohol, ricinoleic alcohol, stearyl alcohol, isostearyl alcohol, cetyl alcohol, lauryl alcohol, myristyl alcohol, arachidyl alcohol, caprylic alcohol, capric alcohol, linoleyl alcohol, linolenyl alcohol and behenyl alcohol are, for example, decanol, octanolol, dodecadienol, decadienol , as well as their Guerbet alcohols, this list should have exemplary and non-limiting character.
  • the fatty alcohols are derived from preferably natural fatty acids, which can usually be based on recovery from the esters of fatty acids by reduction.
  • those fatty alcohol cuts which are produced by reduction of naturally occurring triglycerides such as beef tallow, palm oil, peanut oil, rapeseed oil, cottonseed oil, soybean oil, sunflower oil and linseed oil or fatty acid esters formed from their transesterification products with corresponding alcohols, and thus represent a mixture of different fatty alcohols.
  • Such substances are, for example, under the names Stenol®, eg Stenol® 1618 or Lanette®, eg Lanette® O or Lorol®, eg Lorol® C8, Lorol® C14, Lorol® C18, Lorol® C8-18, HD-Ocenol®, Crodacol®, eg Crodacol® CS, Novol®, Eutanol® G, Guerbitol® 16, Guerbitol® 18, Guerbitol® 20, Isofol® 12, Isofol® 16, Isofol® 24, Isofol® 36, Isocarb® 12, Isocarb® 16 or Isocarb® 24 for sale.
  • wool wax alcohols such as are commercially available under the names Corona®, White Swan®, Coronet® or Fluilan®, can also be used.
  • the fatty alcohols are preferably used in amounts of 0.1-10 wt .-%, based on the total preparation, preferably in amounts of 0.2-5 wt .-%.
  • waxes As natural or synthetic waxes (D3) it is possible according to the invention to use solid paraffins or isoparaffins, carnauba waxes, beeswaxes, candelilla waxes, ozokerites, ceresin, spermaceti, sunflower wax, fruit waxes such as apple wax or citrus wax, microwaxes of PE or PP.
  • Such waxes are available, for example, from Kahl & Co., Trittau.
  • the amount used is 0.1-10 wt.% Based on the total agent, preferably 0.2-8 wt.% And particularly preferably 0.4-5 wt.% Based on the total agent.
  • the natural and synthetic cosmetic oil bodies (D4) include, for example:
  • oils examples include sunflower oil, olive oil, soybean oil, rapeseed oil,
  • Almond oil, jojoba oil, orange oil, wheat germ oil, peach kernel oil and the liquid portions of coconut oil are also suitable, however, are other triglyceride oils such as the liquid portions of beef tallow as well as synthetic triglyceride oils.
  • Ester oils are to be understood as meaning the esters of C 6 -C 30 -fatty acids with C 2 -C 30 -
  • the mono- esters of the fatty acids with alcohols having 2 to 24 carbon atoms are preferred.
  • fatty acid components used in the esters are caproic acid, caprylic acid, 2-ethylhexanoic acid, capric acid, lauric acid, isotridecanoic acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, isostearic acid, oleic acid, elaidic acid, petroselinic acid, linoleic acid, linoleic acid, levostic acid, arachidic acid, gadoleic acid, behenic acid and Erucic acid and their technical mixtures, eg occur in the pressure fission of natural fats and oils, in the oxidation of aldehydes from the Rölen's oxo synthesis or the dimerization of unsaturated fatty acids.
  • fatty alcohol components in the ester oils are isopropyl alcohol, caproic alcohol, capryl alcohol, 2-ethylhexyl alcohol, capric alcohol, lauryl alcohol, isotridecyl alcohol, myristyl alcohol, cetyl alcohol, palmoleyl alcohol, stearyl alcohol, isostearyl alcohol, oleyl alcohol, elaidyl alcohol, petroselinyl alcohol, linolyl alcohol, linolenyl alcohol, estolearyl alcohol, arachyl alcohol, gadoleyl alcohol, Behenyl alcohol, erucyl alcohol and brassidyl alcohol and their technical mixtures, eg incurred in the high-pressure hydrogenation of technical methyl esters based on fats and oils or aldehydes from the Rölen's oxo synthesis and as a monomer fraction in the dimerization of unsaturated fatty alcohols.
  • isopropyl myristate (Rilanit® IPM), C 16-18 alkyl ester (Cetiol® SN), 2-ethylhexyl palmitate (Cegesoft® 24), stearic acid 2-ethylhexyl ester (Cetiol® 868), cetyl oleate, glycerol tricaprylate, coconut fatty alcohol caprinate / caprylate (Cetiol® LC), n-butyl stearate, oleyl erucate (Cetiol® J 600), isopropyl palmitate (Rilanit® IPP), oleyl oleate (Cetiol®), hexyl laurate (Cetiol® A), di-n-butyl adipate (Cetiol® B ), Myristyl myristate (Cetiol®
  • Dicarboxylic acid esters such as di-n-butyl adipate, di (2-ethylhexyl) adipate, di- (2-ethylhexyl) succinate and di-isotridecylvestat and diol esters such as ethylene glycol dioleate, ethylene glycol di-isotridecanoate, propylene glycol di (2 ethylhexanoate), propylene glycol diisostearate, propylene glycol di-pelargonate, butanediol di-isostearate,
  • fatty acid partial glycerides which are monoglycerides, diglycerides and their technical
  • the partial glycerides preferably follow the formula (D4-I) in which R 1 , R 2 and R 3 independently of one another represent hydrogen or a linear or branched, saturated and / or unsaturated acyl radical having 6 to 22, preferably 12 to 18, carbon atoms are provided with the proviso that at least one of these groups is an acyl radical and at least one of these groups is hydrogen.
  • the sum (m + n + q) is 0 or numbers from 1 to 100, preferably 0 or 5 to 25.
  • R 1 is an acyl radical and R 2 and R 3 are hydrogen and the sum (m + n + q) is 0.
  • Typical examples are mono- and / or diglycerides based on caproic, caprylic, 2-ethylhexanoic, capric, lauric, isotridecanoic, myristic, palmitic, palmitic, stearic, isostearic, oleic, elaidic, petroselic, linoleic, linolenic , Elaeostearic acid, arachidic acid, gadoleic acid, behenic acid and erucic acid and their technical mixtures.
  • oleic acid monoglycerides are used.
  • Hair treatment compositions which are preferred according to the invention are characterized in that they contain, based on their weight, from 0.15 to 10% by weight, preferably from 0.2 to 7.5% by weight and in particular from 0.3 to 5% by weight of fatty substances ) from the group of fatty acids, fatty alcohols, natural and synthetic waxes and natural and synthetic cosmetic oil components.
  • compositions according to the invention contain, based on their weight, from 0.001 to 5% by weight of melatonin (I) and / or one of its salts and / or agomelatine (II) and / or one of its salts
  • Melatonin ( ⁇ / -acetyl-5-methoxytryptamine, ILJPAC name ⁇ / - [2- (5-methoxy-1 / - / - indol-3-yl) ethyl] ethanamide) is a hormone derived from the pinealocytes in the Pineal gland (epiphysis) - a part of the diencephalon - from serotonin by acetylation with a dark active N- Acetyltransferase (EC 2.3.1.5) and methylation with / V-acetylserotonin O-methyltransferase (EC 2.1.1.4) is produced.
  • the melatonin causes haariliaende and hair structure improving effects of the hair treatment compositions of the invention.
  • the hair is protected from external influences of chemical (atmospheric influences, hair coloring or perm etc.) or physical (heat, cold, mechanical action, etc.) nature.
  • Hair treatment compositions preferred according to the invention are characterized in that they contain, based on their weight, from 0.0025 to 4% by weight, preferably from 0.005 to 3% by weight, particularly preferably from 0.0075 to 2% by weight, more preferably 0, 01 to 1 wt .-% and in particular 0.01 to 0.5 wt .-% melatonin.
  • agents of the invention may also contain agomelatine.
  • Agomelatine (ILJPAC name N- [2- (7-methoxynaphthalene-1-yl) ethyl] acetamide) is similar in its molecular structure to that of melatonin. The difference lies in the ring system: While melatonin has an indole core, agomelatine has a naphthalene skeleton.
  • Hair treatment compositions preferred according to the invention are characterized in that they contain, based on their weight, from 0.0025 to 4% by weight, preferably from 0.005 to 3% by weight, particularly preferably from 0.0075 to 2% by weight, more preferably 0, 01 to 1 wt .-% and in particular 0.01 to 0.5 wt .-% agomelatine.
  • Melatonin and / or agomelatine are combined in the compositions according to the invention with a care enhancer which is selected from L-carnitine and / or its salts, panthenol and / or pantothenic acid, 2-furanones and / or their derivatives, in particular pantolactone, taurine and / or its salts, niacinamide, ubiquinones, ectoin, allantoin, extracts of echinacea.
  • care enhancers are described below
  • L-carnitine (IUPAC name (R) - (3-carboxy-2-hydroxypropyl) - ⁇ /, ⁇ /, ⁇ / -trimethylammonium hydroxide) is a naturally occurring, vitamin-like substance. It plays an essential role in Energy metabolism of human, animal and plant cells. L-carnitine can be obtained in various ways on an industrial scale. For example, a, the body's own biosynthesis imitating, biotechnological process: In large fermentation tanks while the precursor of L-carnitine ( ⁇ -butyrobetaine) using Gram-negative bacteria (rhizobia) is converted into L-carnitine.
  • L-carnitine can form addition compounds and double salts.
  • L-carnitine derivatives which are preferred according to the invention are selected in particular from acetyl-L-carnitine, L-carnitine fumarate, L-carnitine citrate, lauroyl-L-carnitine and particularly preferably L-carnitine tartrate.
  • the L-carnitine compounds mentioned are available, for example, from Lonza GmbH (Wuppertal, Germany).
  • Preferred hair treatment compositions according to the invention are characterized in that they contain from -0.001 to 10% by weight, preferably 0.005 to 7.5% by weight, particularly preferably 0.01 to 5% by weight and in particular 0.05, based on their weight contain up to 2.5 wt .-% L-carnitine or L-carnitine derivatives, preferred L-carnitine derivatives are selected from acetyl-L-carnitine, L-carnitine fumarate, L-carnitine citrate, lauroyl-L-carnitine and in particular L-carnitine tartrate.
  • Panthenol (ILJPAC name: (+) - (R) -2,4-dihydroxy-N- (3-hydroxypropyl) -3,3-dimethylbutyramide) is converted to pantothenic acid in the body.
  • Pantothenic acid is a vitamin from the group of B vitamins (vitamin B5).
  • Preferred hair treatment compositions according to the invention are characterized in that they contain, based on their weight, from 0.01 to 5% by weight, preferably from 0.05 to 2.5% by weight, particularly preferably from 0.1 to 1.5% by weight. % and in particular 0.25 to 1 wt .-% panthenol (( ⁇ ) -2,4-dihydroxy- ⁇ / - (3-hydroxypropyl) -3,3-dimethyl-butyramide).
  • preferred hair treatment compositions contain - based on their weight - 0.01 to 15 wt .-%, preferably 0.025 to 12.5 wt .-%, particularly preferably 0.05 to 10 wt .-%, more preferably 0.1 to 7 , 5% by weight and in particular 0.5 to 5% by weight of at least one 2-furanone derivative of the formula (Fur-I) and / or of the formula (Fur-II)
  • R 11 as a -C 2 -C 4 -saturated or mono- or diunsaturated, branched or linear hydrocarbon radical, -C 2 -C 4 -saturated or mono- or diunsaturated, branched or linear Mono-, di- or trihydroxyhydrocarbyl radical,
  • R 12 and R 13 each independently represent hydrogen, a methyl, a C 2 -C 4 -saturated or mono- or diunsaturated, branched or linear hydrocarbon radical, a -C 2 -C 4 -saturated or mono- or diunsaturated, branched or linear mono-, di- or trihydroxyhydrocarbyl radical,
  • R 14 is hydrogen, a methyl, a C 2 -C 4 -saturated or mono- or diunsaturated, branched or linear hydrocarbon radical, a -C 2 -C 4 -saturated hydrocarbon radical, or diunsaturated, branched or linear mono-, di- or trihydroxyhydrocarbon hydrocarbon radical, a -C 2 -C 4 -saturated or mono- or diunsaturated, branched or linear mono-, di- or triaminocarbyl radical,
  • R 15 and R 16 each represent hydrogen, methyl, a -C 2 -C 4 -saturated or mono- or diunsaturated, branched or linear hydrocarbon radical, a -C 2 -C 4 - saturated mono- or diunsaturated, branched or linear mono-, di- or trihydroxyhydrocarbyl radical, a -C 2 -C 4 -saturated or mono- or diunsaturated, branched or linear mono-, di- or triaminocarbon radical,
  • R 16 is a methyl, a C 2 -C 4 -saturated or mono- or diunsaturated, branched or linear hydrocarbon radical, a -C 2 -C 4 -saturated or -or- or a diunsaturated, branched or linear mono-, di- or trihydroxy hydrocarbon radical, a -C 2 -C 4 -saturated or mono- or diunsaturated, branched or linear mono-, di- or triaminocarbon radical, - a group -OCOR 17 , wherein R 17 is a methyl, a -C 2 -C 30 -saturated or mono- or polyunsaturated, branched or linear hydrocarbon radical, a -C 2 -C 30 - saturated or on or - polyunsaturated, branched or linear mono-, di-, tri- or Polyhydroxykohlenwasserstoffrest, a -C 2 - C 30 -
  • the compounds of the formulas (Fur-I) and (Fur-II) are used as intermediates in the synthesis of natural products and in the preparation of medicaments and vitamins.
  • the preparation of the active compounds according to the formulas (Fur-I) and (Fur-II) can be carried out, for example, by reacting primary alcohols with acrylic acids.
  • compounds of the formula (Fur-I) are obtained by reactions starting from hydroxypivaldehyde. Also, carbonylations of alkynes lead to substituted 2-furanones of the formula (Fur-I) or (Fur-II).
  • the compounds of the formula (Fur-I) or of the formula (Fur-II) can be obtained by intramolecular esterification of the corresponding hydroxycarboxylic acids.
  • the following compounds are obtained in one of the previously identified synthetic routes: 2,5-dihydro-5-methoxy-2-furanone,
  • Preferred compounds of the formula (fur-I) and / or of the formula (fur-II) can be compounds in which the substituents R 1 , R 2 and R 7 independently of one another represent:
  • R 11 as a -C 2 -C 4 -saturated or mono- or diunsaturated, branched or linear hydrocarbon radical, -C 2 -C 4 -saturated or mono- or diunsaturated, branched or linear Mono-, di- or trihydroxyhydrocarbyl radical, a group -NR 12 R 13 , wherein R 12 and R 13 each independently represent hydrogen, a methyl, a C 2 -C 4 -saturated or mono- or diunsaturated, branched or linear hydrocarbon radical, a -C 2 C 4 - saturated or mono- or diunsaturated, branched or linear mono-, di- or trihydroxyhydrocarbon radical,
  • R 14 is hydrogen, a methyl, a C 2 -C 4 -saturated or mono- or diunsaturated, branched or linear hydrocarbon radical, a -C 2 -C 4 -saturated or - or diunsaturated, branched or linear mono-, di- or trihydroxy hydrocarbon radical, a -C 2 -C 4 -saturated or mono- or diunsaturated, branched or linear mono-, di- or triaminocarbon radical,
  • R 16 is a methyl, a C 2 -C 4 -saturated or mono- or diunsaturated, branched or linear hydrocarbon radical, a -C 2 -C 4 -saturated or -or- or diunsaturated, branched or linear mono, di-trihydroxy hydrocarbon radical, a -C 2 -C 4 -saturated or mono- or diunsaturated, branched or linear mono-, di- or triaminocarbyl radical,
  • R 17 is a methyl, a -C 2 -C 30 -saturated or mono- or polyunsaturated, branched or linear hydrocarbon radical, a - C 2 - C 30 - saturated or on or - polyunsaturated, branched or linear mono-, di-, tri- or polyhydroxyalkyl radical, or a -C 2 - C 30 - saturated or mono- or polyunsaturated, branched or linear mono-, di-, tri- or polyamino hydrocarbon radical.
  • Hydrogen an -OH, a methyl, methoxy, aminomethyl, hydroxymethyl, a -C 2 -C 4 - saturated or mono- or diunsaturated, branched or linear
  • Hydrocarbon radical a -C 2 - C 4 - saturated or mono- or diunsaturated, branched or linear
  • radicals R 5 , R 6 , R 9 and R 10 in the active substance according to the formula (I) and / or formula (II) according to the invention may stand independently of one another for:
  • Hydrocarbon radical - a -C 2 - C 4 - saturated or mono- or diunsaturated, branched or linear
  • a compound of the formula (Fur-I) is used. It may be preferred that in a compound of the formula (fur-I), the radicals R 1 and R 2 are independently of one another:
  • R 11 as a -C 2 -C 4 -saturated or mono- or diunsaturated, branched or linear hydrocarbon radical, -C 2 -C 4 -saturated or mono- or diunsaturated, branched or linear Mono-, di- or trihydroxyhydrocarbyl radical,
  • R 14 is hydrogen, a methyl, a C 2 -C 4 -saturated or mono- or diunsaturated, branched or linear hydrocarbon radical, a -C 2 -C 4 -saturated hydrocarbon radical, or diunsaturated, branched or linear mono-, di- or trihydroxyhydrocarbyl radical,
  • R 16 is a methyl, a C 2 -C 4 -saturated or mono- or diunsaturated, branched or linear hydrocarbon radical, a -C 2 -C 4 -saturated or -or- or diunsaturated, branched or linear mono, di-trihydroxy hydrocarbon radical,
  • R 17 is a methyl, a -C 2 -C 30 -saturated or mono- or polyunsaturated, branched or linear hydrocarbon radical, a - C 2 - C 30 - saturated or on or - polyunsaturated, branched or linear mono-, di-, tri- or Polyhydroxykohlenwasserstoffrest.
  • Hydrogen an -OH, a methyl, methoxy, aminomethyl, hydroxymethyl, a -C 2 -C 4 - saturated or mono- or diunsaturated, branched or linear
  • Mono-, di- or trihydroxyhydrocarbyl radical a group -OR 11 , with R 11 as a -C 2 -C 4 -saturated or mono- or diunsaturated, branched or linear hydrocarbon radical, -C 2 -C 4 -saturated or or diunsaturated, branched or linear mono-, di- or
  • Trihydroxykohlenwasserstoffrest a group -COOR 14 , wherein R 14 is hydrogen, a methyl, a C 2 -C 4 -saturated or mono- or diunsaturated, branched or linear hydrocarbon radical, a -C 2 -C 4 - saturated on- or a di-unsaturated, branched or linear mono-, di- or trihydroxy hydrocarbon radical, a group -OCOR 17 , where R 17 is a methyl, C 2 -C 30 -saturated or mono- or polyunsaturated, branched or linear hydrocarbon radical, a -C 2 - C 30 - saturated or mono- or polyunsaturated, branched or linear mono-, di-, tri- and / or polyhydroxy hydrocarbon radical.
  • radicals R 5 and R 6 may furthermore be advantageous for the compounds of the formula (Fur I) for the radicals R 5 and R 6 to stand independently for: a C 2 -C 4 -saturated or mono- or diunsaturated, branched or linear
  • Mono-, di- or trihydroxyhydrocarbyl radical a group -OR 11 , with R 11 as a -C 2 -C 4 -saturated or mono- or diunsaturated, branched or linear hydrocarbon radical, -C 2 -C 4 -saturated or or diunsaturated, branched or linear mono-, di- or
  • a very particularly preferred embodiment of the teaching according to the invention is used as a compound according to the formula (Fur-I) dihydro-3-hydroxy-4,4-dimethyl-2 (3H) - furanone.
  • Another preferred care enhancer which has activating properties is taurine.
  • preferred hair treatment compositions contain - based on their weight - 0.01 to 15 wt .-%, preferably 0.025 to 12.5 wt .-%, particularly preferably 0.05 to 10 wt .-%, more preferably 0.1 to 7 , 5 wt .-% and in particular 0.5 to 5 wt .-% taurine (2-aminoethanesulfonic acid).
  • compositions of the invention are vitamins, provitamins or vitamin precursors. These are described below:
  • vitamin A includes retinol (vitamin A 1 ) and 3,4-didehydroretinol (vitamin A 2 ).
  • the ß-carotene is the provitamin of retinol.
  • vitamin A component according to the invention for example, vitamin A acid and its esters, vitamin A aldehyde and vitamin A alcohol and its esters such as the palmitate and the acetate into consideration.
  • the agents according to the invention preferably contain the vitamin A component in amounts of 0.05-1% by weight, based on the total preparation.
  • the vitamin B group or the vitamin B complex include vitamin B 1 (thiamine) vitamin B 2 (riboflavin)
  • Vitamin B 3 the compounds nicotinic acid and nicotinamide (niacinamide) are often performed.
  • Preferred according to the invention is the nicotinic acid amide which is contained in the agents used according to the invention preferably in amounts of from 0.05 to 1% by weight, based on the total agent.
  • Vitamin B 5 pantothenic acid, panthenol and pantolactone.
  • Panthenol and / or pantolactone are preferably used in the context of this group (see below).
  • Derivatives of panthenol which can be used according to the invention are, in particular, the esters and ethers of panthenol and also cationically derivatized panthenols. Individual representatives are, for example, the panthenol triacetate, the panthenol monoethyl ether and its monoacetate and also the cationic panthenol derivatives disclosed in WO 92/13829.
  • the said compounds of the vitamin B 5 type are preferably contained in the agents according to the invention in amounts of 0.05-10% by weight, based on the total agent. Amounts of 0.1-5 wt .-% are particularly preferred. Vitamin B 6 (pyridoxine and pyridoxamine and pyridoxal).
  • Vitamin C (ascorbic acid). Vitamin C is used in the agents according to the invention preferably in amounts of 0.1 to 3 wt .-%, based on the total agent. Use in the form of palmitic acid ester, glucosides or phosphates may be preferred. The use in combination with tocopherols may also be preferred. Vitamin E (tocopherols, especially ⁇ -tocopherol). Tocopherol and its derivatives, which include in particular the esters such as the acetate, the nicotinate, the phosphate and the succinate, are preferably present in the agents according to the invention in amounts of 0.05-1% by weight, based on the total agent.
  • Vitamin F is usually understood as meaning essential fatty acids, in particular linoleic acid, linolenic acid and arachidonic acid.
  • Vitamin H is the compound (3aS, 4S, 6aR) -2-oxohexahydrothienol [3,4-cf] - imidazole-4-valeric acid, for which, however, the trivial name biotin has meanwhile prevailed.
  • Biotin is preferably present in the compositions according to the invention in amounts of from 0.0001 to 1.0% by weight, in particular in amounts of from 0.001 to 0.01% by weight.
  • hair-treatment compositions according to the invention are preferred which, based on their weight, are 0.1 to 5% by weight, preferably 0.2 to 4% by weight, more preferably 0.25 to 3.5% by weight, more preferably Contain 0.5 to 3 wt .-% and in particular 0.5 to 2.5 wt .-% vitamins and / or pro-vitamins and / or vitamin precursors, preferably the groups A, B, C, E, F and H.
  • vitamin B 5 2,4-dihydroxy- ⁇ / - (3-hydroxypropyl) -3,3-dimethylbutyramide, provitamin B 5 ) and / or pantothenic acid (vitamin B 3 , vitamin B 5 ) and / or Niacin, niacinamide or nicotinamide (vitamin B 3 ) and / or L-ascorbic acid (vitamin C) and / or thiamine (vitamin B 1 ) and / or riboflavin (vitamin B 2 , vitamin G) and / or biotin (vitamin B 7 , Vitamin H) and / or folic acid (vitamin B 9 , vitamin B c or vitamin M) and / or vitamin B 6 and / or vitamin B 12 .
  • compositions according to the invention may therefore contain from 0.0001 to 5% by weight of at least one biochinone of the formula (Ubi)
  • X, Y, Z are independently -O- or -NH- or NR 4 - or a chemical bond
  • R 1 , R 2 , R 3 independently of one another represent a hydrogen atom or an optionally substituted aryl group or an optionally substituted (C 1 -C 6 ) -alkyl group or a hydroxyalkyl group or a Polyhydroxyalkyl group or an optionally substituted (C 1 -Ce) -
  • Alkylene group or a (C-rC 6 ) acyl radical, wherein preferred radicals are independently selected from -H, -CH 3 , -CH 2 CH 3 ,
  • R 4 is -CH 3 , -CH 2 CH 3 , - (CH 2 ) 2 CH 2 , -CH (CH 3 ) 2 , - (CH 2 ) 3 CH 3 ,
  • -CH (CH 3 ) CH 2 CH 3 , -CH 2 CH (CH 3 ) 2 , -C (CH 3 ) 3 is from 1 to 20, preferably from 2 to 15 and in particular from 5 to 6, 7, 8, 9, 10.
  • Preferred compounds of the formula (Ubi) according to the invention are, for example
  • R 1 , R 2 , R 3 are each independently -H, -CH 3 , -CH 2 CH 3 , - (CH 2 ) 2 CH 2 , -CH (CH 3 ) 2 , - (CH 2 ) 3 CH 3 , -CH (CH 3 ) CH 2 CH 3 , -CH 2 CH (CH 3 ) 2 , -C (CH 3 ) 3
  • R 4 is -CH 3 , or -CH 2 CH 3 , or - (CH 2 ) 2 CH 2 , or -CH (CH 3 ) 2 n is from 1 to 20, preferably from 2 to 15 and especially for 5, 6, 7, 8, 9, 10.
  • Particularly preferred hair treatment compositions according to the invention are characterized in that they contain as care substance - based on their weight - 0.0001 to 1 wt .-%, preferably 0.001 to 0.5 wt .-% and particularly preferably 0.005 to 0, 1 wt .-% containing at least one ubiquinone and / or at least one ubiquinol and / or at least one derivative of these substances, preferred agents containing a ubiquinone of the formula (Ubi)
  • n 6, 7, 8, 9 or 10, particularly preferably 10 (coenzyme Q10).
  • the agents according to the invention may also contain plastoquinones.
  • preferred agents according to the invention are characterized in that they are 0.0002 to 4 wt .-%, preferably 0.0005 to 3 wt .-%, particularly preferably 0.001 to 2 wt .-%, more preferably 0.0015 to 1 and in particular 0.002 to 0.5 wt .-% of at least one plastoquinone of the formula (Ubi-b)
  • n stands for values of 1 to 20, preferably of 2 to 15 and in particular for 5, 6, 7, 8, 9, 10, whereby particularly preferred means Plastochinon PQ-9 of the formula
  • the agents according to the invention may contain ectoin.
  • Ectoine ((4S) - 2-methyl-1, 4,5,6-tetrahydropyrimidine-4-carboxylic acid) is a natural product belonging to the group of compatible solutes. The highly water-binding low molecular weight organic compound occurs in halophilic bacteria and allows these extremophilic organisms to survive under stress conditions.
  • Hair treatment compositions which are preferred according to the invention are characterized in that they contain, based on their weight, from 0.001 to 10% by weight, preferably from 0.01 to 5% by weight, particularly preferably from 0.05 to 2.5% by weight and in particular from 0 , 1 to 1% by weight of (S) -2-methyl-1, 4,5,6-tetrahydro-4-pyrimidinecarboxylic acid (ectoine) and the physiologically tolerated salts of this compound and / or (S, S) -5- Hydroxy-2-methyl-1, 4,5,6-tetrahydro-4-pyrimidinecarboxylic acid (hydroxyectoine) and the physiologically acceptable salts of this compound.
  • S -2-methyl-1, 4,5,6-tetrahydro-4-pyrimidinecarboxylic acid
  • hydroxyectoine hydroxyectoine
  • Allantoin (5-ureido-hydantoin, ⁇ / - (2,5-dioxo-4-imidazolidinyl) urea) is the final product of nucleic acid degradation, especially purine, in various animal species, especially mammals. Allantoin is used in cosmetics in skin creams, sunscreens, shampoos, toothpaste and anti-sweating (hyperhidrosis) and skin irritants. It accelerates cell building, cell formation or cell regeneration and calms the skin. The healing of hard-healing wounds is also supported, but allantoin has no antiseptic properties.
  • particularly preferred hair treatment compositions contain, based on their weight, from 0.001 to 10% by weight, preferably from 0.01 to 5% by weight, particularly preferably from 0.05 to 2.5% by weight and in particular from 0.1 to 1 5% ureidohydantoin (allantoin).
  • plants are extra kte.
  • extracts are produced by extraction of the whole plant. However, in individual cases it may also be preferred to prepare the extracts exclusively from flowers and / or leaves of the plant.
  • alcohols and mixtures thereof can be used as extraction agent for the preparation of said plant extracts water.
  • the alcohols are lower alcohols such as ethanol and isopropanol, but especially polyhydric alcohols such as ethylene glycol and propylene glycol, both as the sole extractant and in admixture with water, prefers.
  • Plant extracts based on water / propylene glycol in a ratio of 1:10 to 10: 1 have proven to be particularly suitable.
  • the plant extracts can be used according to the invention both in pure and in diluted form. If they are used in diluted form, they usually contain about 2 to 80 wt .-% of active substance and as a solvent used in their extraction agent or extractant mixture.
  • compositions according to the invention mixtures of several, especially two, different plant extracts.
  • Echinacea Especially preferred are extracts of Echinacea or Moringa plants, with Echinacea extracts being particularly preferred.
  • the genus of coneflower (Echinaceae) includes North American perennials, some of which have long been used for the supportive treatment of infections (internal) and wounds (external).
  • Echinacea extracts are known to be used to stimulate the immune system and as an antimicrobial and antiviral substance
  • the plant extracts from plants of the genus Echinacea can from various Finhutgewumblesen (Echinacea, synonym: Brauneria NECKER), in particular from Echinacea angustifolia DC, Echinacea paradoxa (NORTON), Echinacea simulata, E. atrorubens, E. tennesiensis, Echinacea strigosa (MCGREGOR), Echinacea laevigata, Echinacea purpurea (L.) Moench and Echinacea pallida (Nutt), as well as from these extracts to be recovered active substances. Extracts of coneflower plants, in particular Echinacea purpurea (L) MOENCH, are particularly preferably used.
  • the extracts are preferably obtained from cabbage (the above-ground parts of plants) and / or root of the coneflower family.
  • the extracts may be prepared with water, as well as polar or nonpolar organic solvents, as well as mixtures thereof in a manner known to those skilled in the art. Extracts that can be obtained by extraction with ethanol or water / ethanol mixtures and press juice are preferred.
  • extracts both in the original extractant and extracts / compressed juice in water or other organic solvents and / or mixtures thereof, in particular ethanol and ethanol / water mixtures.
  • extracted or pressed material is used as a solid to which the solvent (in particular as gently as possible) was removed.
  • those extracts / compressed juices to which the solvent has been partly removed, so that a thickened extract / compressed juice is used.
  • Very particular preference is given to pressed juices from the fresh Echinacea purpurea herb (Echinacea purpurea Moench herba).
  • the extracts and / or compressed juices are used in solid form.
  • particularly preferred hair treatment compositions are characterized in that they - based on their weight - 0.001 to 10 wt .-%, in particular 0.01 to 2 wt .-% active ingredient, obtainable from plants of the genus Echinacea, preferably from pressed juices and extracts, the are obtained from Echinacea purpurea.
  • compositions according to the invention may contain purine and / or purine derivatives as care-enhancing agents.
  • purine and / or purine derivatives with ubiquinones and / or plastoquinones as skin care enhancers means that the hairs treated with appropriate agents show, inter alia, higher measured values in differential thermal analysis and improved wet and dry combabilities.
  • Purine (7 / - / - imidazo [4,5-cf] pyrimidine) does not occur freely in nature, but forms the main body of purines.
  • Purines are a group of important compounds of widespread nature involved in human, animal, plant and microbial metabolic processes, which differ from the parent by substitution with OH, NH 2 , SH in the 2-, 6-, and 8-positions and / or with CH 3 in 1-, 3-, 7-position derived.
  • Purine can be prepared, for example, from aminoacetonitrile and formamide.
  • Purines and purine derivatives are often isolated from natural products, but are also synthetically accessible in many ways.
  • Preferred agents according to the invention contain purine and / or purine derivatives in narrower quantitative ranges.
  • inventively preferred cosmetic agents characterized in that they - based on their weight - 0.001 to 2.5 wt .-%, preferably 0.0025 to 1 wt .-%, particularly preferably 0.005 to 0.5 wt .-% and in particular from 0.01 to 0.1% by weight of purine (s) and / or purine derivative (s).
  • Hair treatment compositions which are preferred according to the invention are characterized in that they contain, as care-enhancers, based on their weight, from 0.001 to 2.5% by weight, preferably from 0.0025 to 1% by weight, particularly preferably from 0.005 to 0.5% by weight.
  • agents according to the invention are preferred in which the weight ratio of purine (derivative (s)) and biochinone (s) is 10: 1 to 1: 100, preferably 5: 1 to 1:50, particularly preferably 2: 1 to 1:20 and in particular 1: 1 to 1:10.
  • caffeine is a particularly preferred purine derivative
  • coenzyme Q10 is a particularly preferred biochinone.
  • Particularly preferred agents according to the invention are therefore characterized in that they contain, based on their weight, from 0.001 to 2.5% by weight, preferably from 0.0025 to 1% by weight, particularly preferably from 0.005 to 0.5% by weight and in particular 0.01 to 0.1 wt .-% caffeine and 0.0002 to 4 wt .-%, preferably 0.0005 to 3 wt .-%, particularly preferably 0.001 to 2 wt .-%, more preferably 0.0015 to 1 and in particular 0.002 to 0.5 wt .-% coenzyme Q10 included.
  • the agents according to the invention may also contain flavonoids.
  • the flavonoids are a group of water-soluble plant dyes and play an important role in the metabolism of many plants. They belong together with the phenolic acids to the polyphenols.
  • flavonoids from all six groups can be used, with certain representatives from the individual groups being preferred as care enhancers because of their particularly intensive action.
  • Preferred flavonols are quercetin, rutin, kaempferol, myricetin, isorhamnetin, preferred flavanols are catechin, gallocatechin, epicatechin, epigallocatechin gallate, theaflavin, thearubigin, preferred flavones are luteolin, apigenin, morin, preferred flavanones are hesperetin, naringenin, eriodictyol, preferred isoflavonoids are genistein , Daidzein, and preferred anthocyanidins (anthocyanins) are cyanidin, delphinidin, malvidin, pelargonidin, peonidin, petunidin.
  • particularly preferred hair treatment compositions are characterized in that they - based on their weight - 0.001 to 2.5 wt .-%, preferably 0.0025 to 1 wt .-%, particularly preferably 0.005 to 0.5 wt .-% and in particular 0.01 to 0.1% by weight of flavonoids, in particular flavonols, more preferably 3,3 ', 4', 5,7-pentahydroxyflavone (quercetin) and / or 3,3 ', 4', 5,7-pentahydroxyflavone -3-O-rutinoside (rutin), included.
  • flavonoids in particular flavonols, more preferably 3,3 ', 4', 5,7-pentahydroxyflavone (quercetin) and / or 3,3 ', 4', 5,7-pentahydroxyflavone -3-O-rutinoside (rutin), included.
  • hair treatment compositions according to the invention which additionally contain 0.001 to 5 wt .-%, preferably 0.01 to 4 wt .-%, particularly preferably 0.02 to 2.5 wt .-% and in particular 0.1 to 1, 5 wt % Bisabolol and / or oxides of bisabolol, preferably (-) - alpha-bisabolol
  • Creatine is an organic acid found in vertebrates and the like. a. contributes to supplying the muscles with energy. Creatine is synthesized in the kidney, liver and pancreas. It is formally derived from the amino acids glycine and arginine and is 95% present in skeletal muscle.
  • Particularly preferred hair treatment compositions according to the invention contain - based on their weight - 0.01 to 15 wt .-%, preferably 0.025 to 12.5 wt .-%, particularly preferably 0.05 to 10 wt .-%, more preferably 0.1 to 7.5 wt .-% and in particular 0.5 to 5 wt .-% ⁇ / -methyl-guanidino-acetic acid (creatine).
  • compositions according to the invention may contain, in addition to the aforementioned ingredients and optional further ingredients, other substances which prevent, alleviate, or alleviate hair loss heal.
  • other substances which prevent, alleviate, or alleviate hair loss heal.
  • a content of hair root stabilizing agents is advantageous.
  • Propecia (Finasteride) is currently the only preparation that is approved worldwide and has been proven in many studies to be effective and tolerable. Propecia causes less DHT to form from testosterone.
  • Minoxidil is probably the oldest proven hair restorer with or without supplemental additives. For the treatment of hair loss, it may only be used for external application. There are hair lotions containing 2% -5% minoxidil, as well as gels with up to 15% minoxidil. The effectiveness increases with the dosage, in hair waters Minoxidil is only up to 5% share soluble. In many countries, hair tonic with up to 2% minoxidil content is available without prescription.
  • spironolactone in the form of hair tonic and in combination with minoxidil can be used for external application.
  • Spironolactone acts as an androgen receptor blocker, ie. the binding of DHT to the hair follicles is prevented.
  • hair treatment compositions according to the invention are preferred which additionally contain, based on their weight, from 0.001 to 5% by weight of hair root stabilizing substances, in particular minoxidil and / or finasteride and / or ketoconazole.
  • Additional antidandruff active ingredients for example climbazole, piroctone olamine or zinc pyrithione
  • climbazole, piroctone olamine or zinc pyrithione are used to purposefully reduce the amount of dandruff causing the dandruff, to restore the normal bacterial count to the normal percentage and to reduce the scaling to the physiological level.
  • laboratory tests have shown that the different species representatives of Pityrosporum ovale react differently to the antidandruff active ingredients. In order to maximally combat all dandruff is therefore a combination of anti-dandruff active ingredients most successful.
  • hair treatment compositions according to the invention which additionally comprise, based on their weight, from 0.001 to 5% by weight of antidandruff active ingredients, in particular piroctone olamine (1-hydroxy-4-methyl-6- (2,4,4-tri-methylpentyl) -pyridine-2 ( 1 H) -one, compound with 2-aminoethanol, 1: 1) and / or zinc pyrithione and / or selenium sulfide and / or climbazole and / or salicylic acid or fumaric acid.
  • antidandruff active ingredients in particular piroctone olamine (1-hydroxy-4-methyl-6- (2,4,4-tri-methylpentyl) -pyridine-2 ( 1 H) -one, compound with 2-aminoethanol, 1: 1) and / or zinc pyrithione and / or selenium sulfide and / or climbazole and / or salicylic acid or fumaric acid.
  • the agents according to the invention may contain further care substances. Their presence is not absolutely necessary for achieving the effects according to the invention, but further effects, such as a pleasant touch or a pleasant application feel, can result from the use of these care substances.
  • the agents according to the invention may with particular preference contain one or more amino acids.
  • Preferred agents according to the invention contain one or more amino acids in narrower quantitative ranges.
  • preferred hair treatment compositions are characterized in that they as care substance - based on their weight - 0.01 to 5 wt .-%, preferably 0.02 to 2.5 wt .-%, particularly preferably 0.05 to 1, 5 Wt .-%, more preferably 0.075 to 1 wt .-% and in particular 0.1 to 0.25 wt .-% amino acid (s), preferably from the group of glycine and / or alanine and / or valine and / or lysine and / or leucine and / or threonine.
  • the agents according to the invention may contain at least one carbohydrate from the group of monosaccharides, disaccharides and / or oligosaccharides.
  • preferred hair treatment compositions according to the invention characterized in that they are used as care substance - based on their weight - 0.01 to 5 wt .-%, preferably 0.05 to 4.5 wt .-%, particularly preferably 0.1 to 4 wt. -%, more preferably 0.5 to 3.5 wt .-% and in particular 0.75 to 2.5 wt .-% carbohydrate (s) selected from monosaccharides, disaccharides and / or oligosaccharides containing preferred carbohydrates are selected from Monosachhariden, in particular
  • Particularly preferred agents according to the invention contain based on their weight
  • preferred agents according to the invention contain (a) amino acid (s).
  • Preferred agents according to the invention contain one or more amino acids in narrower quantitative ranges.
  • preferred cosmetic agents are characterized in that they additionally contain from 0.05 to 5% by weight, preferably from 0.1 to 2.5% by weight, more preferably from 0.15 to 1% by weight and in particular from 0 , 2 to 0.5 wt .-% amino acid (s), preferably (one) amino acid (s) from the group glycine and / or alanine and / or valine and / or lysine and / or leucine and / or threonine.
  • Particularly preferred agents according to the invention contain based on their weight
  • valine 0.1 to 0.25% by weight of valine
  • a particularly preferred group of ingredients are the silicones.
  • Preferred agents according to the invention are characterized in that they comprise at least one silicone, preferably a silicone, selected from:
  • polyalkyl siloxanes polyaryl siloxanes, polyalkylaryl siloxanes which are volatile or nonvolatile, straight chain, branched or cyclic, crosslinked or uncrosslinked;
  • grafted silicone polymers having a non-silicone organic backbone consisting of an organic backbone formed from organic monomers containing no silicone grafted with at least one polysiloxane macromer in the chain and optionally at least one chain end; (v) grafted polysiloxane backbone silicone polymers having grafted thereto non-silicone organic monomers having a polysiloxane backbone to which at least one organic macromer not containing silicone has been grafted in the chain, and optionally at least at one of its ends ; or their mixtures.
  • compositions according to the invention comprise the silicone (s) preferably in amounts of from 0.1 to 10% by weight, preferably from 0.25 to 7% by weight and in particular from 0.5 to 5% by weight. , in each case based on the total mean.
  • x is a number from 0 to 100, preferably from 0 to 50, more preferably from 0 to 20 and in particular 0 to 10.
  • silicones are called DIMETHICONE according to the INCI nomenclature.
  • the compounds are preferably:
  • compositions of the invention may be included in the compositions of the invention.
  • silicones have viscosities at 20 0 C for from 0.2 to 2 mmV 1, wherein silicones having viscosities of 0.5 to 1 mmV 1 are particularly preferred.
  • Particularly preferred agents according to the invention contain one or more amino-functional silicones.
  • Such silicones may e.g. through the formula
  • R in the above formula is a hydrocarbon or a hydrocarbon group of 1 to about 6 carbon atoms
  • Q is a polar group of the general formula -R 1 HZ wherein R 1 is a divalent linking group attached to hydrogen and the group Z is an organic, amino-functional radical containing at least one amino-functional group, carbon and hydrogen atoms, carbon, hydrogen and oxygen atoms or carbon, hydrogen and nitrogen atoms;
  • "a” assumes values in the range of about 0 to about 2
  • "b” assumes values in the range of about 1 to about 3
  • "a” + "b” is less than or equal to 3
  • "c” is a number in the range from about 1 to about 3
  • x is a number ranging from 1 to about 2,000, preferably from about 3 to about 50, and most preferably from about 3 to about 25
  • y is a number ranging from about 20 to about 10,000 , preferably from about 125 to about 10,000, and most preferably from about 150 to about 1,000
  • M is a
  • Non-limiting examples of the groups represented by R include alkyl groups such as methyl, ethyl, propyl, isopropyl, isopropyl, butyl, isobutyl, amyl, isoamyl, hexyl, isohexyl and the like; Alkenyl radicals such as vinyl, halovinyl, alkylvinyl, allyl, haloallyl, alkylallyl; Cycloalkyl radicals such as cyclobutyl, cyclopentyl, cyclohexyl and the like; Phenyl radicals, benzyl radicals, halohydrocarbon radicals such as 3-chloropropyl, A-bromobutyl, 3,3,3-trifluoropropyl, chlorocyclohexyl, bromophenyl, chlorophenyl and the like, and sulfur-containing radicals such as mercaptoethyl, mercaptopropyl,
  • R 1 examples include methylene, ethylene, propylene, hexamethylene, decamethylene, -CH 2 CH (CH 3 ) CH 2 -, phenylene, naphthylene, -CH 2 CH 2 SCH 2 CH 2 -, - CH 2 CH 2 OCH 2 - , -OCH 2 CH 2 -, -OCH 2 CH 2 CH 2 -, -CH 2 CH (CH 3 ) C (O) OCH 2 -, - (CH 2 ) 3 CC (O) OCH 2 CH 2 -, C 6 H 4 C 6 H 4 -, -C 6 H 4 CH 2 C 6 H 4 -; and - (CH 2 ) 3 C (O) SCH 2 CH 2 -.
  • Z is an organic, amino-functional radical containing at least one functional amino group.
  • a possible formula for Z is NH (CH 2 ) Z NH 2 , wherein z is 1 or more.
  • Another possible formula for Z is -NH (CH 2 ) Z (CH 2 ) ZZ NH, wherein both z and zz are independently 1 or more, which structure includes diamino ring structures, such as piperazinyl.
  • Z is most preferably a -NHCH 2 CH 2 NH 2 radical.
  • Z is - N (CH 2 ) Z (CH 2 ) ZZ NX 2 or -NX 2 , wherein each X of X 2 is independently selected from the group consisting of hydrogen and alkyl groups of 1 to 12 carbon atoms, and zz is 0.
  • Q is most preferably a polar, amine functional group of the formula CH 2 CH 2 CH 2 NHCH 2 CH 2 NH 2 .
  • "a” assumes values in the range of about 0 to about 2
  • "b” assumes values in the range of about 2 to about 3
  • "a” + “b” is less than or equal to 3
  • the molar ratio of R 3 Q b SiO (4 a -. b) / 2 units to the R 0 SiO (. 4 C) / 2 units is in the range from about 1: 2 to 1:65, preferably from about 1: 5 to about 1:65, and most preferably from about 1:15 to about 1:20.
  • the various variables can be used Substituents in the above formula may be different for the various silicone components present in the silicone blend.
  • Preferred agents according to the invention are characterized in that they contain an amino-functional silicone of the formula (Si-II)
  • G is -H, a phenyl group, -OH, -O-CH 3 , -CH 3 , -O-CH 2 CH 3 , -CH 2 CH 3 , -O-
  • a is a number between O and 3, in particular O;
  • b is a number between 0 and 1, in particular 1,
  • n and n are numbers whose sum (m + n) is between 1 and 2000, preferably between 50 and 150, where n is preferably values from 0 to 1999 and in particular from 49 to 149 and m preferably values from 1 to 2000, in particular from 1 to 10,
  • R ' is a monovalent radical selected from O -QN (R ") - CH 2 -CH 2 -N (R") 2 o -QN (R ") 2 o -QN + (R") 3 A- o - QN + H (R ") 2 A- o -QN + H 2 (R ") A " o -QN (Fn-CH 2 -CH 2 -N + R 11 H 2 A " where each Q is a chemical bond, -CH 2 -, -CH 2 - CH 2 -, -CH 2 CH 2 CH 2 -, -C (CH 2 ) 2 -, -CH 2 CH 2 CH 2 CH 2 -, -CH 2 C (CH 3 ) 2 -, -CH (CH 3 ) CH 2 CH 2 -, R "represents identical or different radicals from the group -H, -phenyl, -benzyl, -CH 2 - CH (CH 3) Ph, the C-
  • A represents an anion, which is preferably selected from chloride, bromide, iodide or methosulfate.
  • Particularly preferred agents according to the invention are characterized in that they contain at least one amino-functional silicone of the formula (Si-IIa)
  • n and n are numbers whose sum (m + n) is between 1 and 2000, preferably between 50 and 150, where n preferably values of 0 to 1999 and in particular of 49 to 149 and m preferably values of 1 to 2000 , in particular from 1 to 10 assumes.
  • silicones are referred to as trimethylsilylamodimethicones according to the INCI declaration.
  • agents according to the invention which are an amino-functional silicone of the formula (Si-IIb)
  • n1 and n2 are numbers whose sum (m + n1 + n2) is between 1 and 2,000, preferably between 50 and 150 , where the sum (n1 + n2) preferably assumes values from 0 to 1999 and in particular from 49 to 149 and m preferably values from 1 to 2000, in particular from 1 to 10.
  • silicones are referred to as amodimethicones according to the INCI declaration.
  • agents according to the invention which contain an amino-functional silicone whose amine number is above 0.25 meq / g, preferably above 0.3 meq / g and in particular above 0.4 meq / g.
  • the amine number stands for the milliequivalents of amine per gram of the amino-functional silicone. It can be determined by titration and also expressed in mg KOH / g.
  • Agents preferred according to the invention are characterized in that, based on their weight, they contain 0.01 to 10% by weight, preferably 0.1 to 8% by weight, particularly preferably 0.25 to 7.5% by weight and in particular 0, 5 to 5 wt.% Amino-functional silicone (s) included.
  • agents according to the invention which contain at least one silicone of the formula Si-III
  • x is a number from 3 to 200, preferably from 3 to 10, more preferably from 30 to 7 and in particular 3, 4, 5 or 6.
  • the silicones described above have a backbone composed of -Si-O-Si units.
  • these Si-O-Si units may also be interrupted by carbon chains.
  • Appropriate molecules are accessible by chain extension reactions and are preferably used in the form of silicone-in-water emulsions.
  • R is identical or different radicals from the group -H, -phenyl, -benzyl, -CH 2 -CH (CH 3 ) Ph, the d-zo-alkyl radicals, preferably -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH (CH 3 ) 2 , -CH 2 CH 2 CH 2 H 3 , -CH 2 CH (CH 3 ) 2 , -CH (CH 3 ) CH 2 CH 3 , -C (CH 3 ) 3 , x and y are a number from 0 to 200, preferably from 0 to 10, more preferably from 0 to 7 and in particular 0, 1, 2, 3, 4, 5 or 6, and n is a number from 0 to 10, preferably from 1 to 8 and in particular from 2, 3, 4, 5, 6.
  • the silicones are preferably water-soluble. Agents preferred according to the invention are characterized in that they contain at least one water-soluble silicone.
  • hair treatment agents which are preferred according to the invention are therefore characterized by being transparent or translucent.
  • NTU Nephelometrie Turbidity Unit
  • an agent according to the invention may also contain UV filters (I).
  • the UV filters to be used according to the invention are not subject to any general restrictions with regard to their structure and their physical properties. On the contrary, all UV filters which can be used in the cosmetics sector and whose absorption maximum is in the UVA (315-400 nm), in the UVB (280-315 nm) or in the UVC ( ⁇ 280 nm) range are suitable. UV filters with an absorption maximum in the UVB range, in particular in the range from about 280 to about 300 nm, are particularly preferred.
  • the UV filters used according to the invention can be selected, for example, from substituted benzophenones, p-aminobenzoic acid esters, diphenylacrylic acid esters, cinnamic acid esters, salicylic acid esters, benzimidazoles and o-aminobenzoic acid esters.
  • UV filters which can be used according to the invention are 4-aminobenzoic acid, N, N, N-trimethyl-4- (2-oxoborn-3-ylidenemethyl) aniline methylsulfate, 3,3,5-trimethylcyclohexyl salicylate (homosalates), 2-hydroxy-4-methoxy-benzophenone (benzophenone-3; Uvinul ® M 40, Uvasorb MET ®, ® Neo Heliopan BB, Eusolex ® 4360), 2-phenylbenzimidazole-5-sulfonic acid and potassium, sodium and triethanolamine salts ( Phenylbenzimidazole sulfonic aeid; Parsol ® HS; Neo Heliopan Hydro ®), 3,3 '- (1, 4-phenylenedimethylene) bis (7,7-dimethyl-2-oxo-bicyclo [2.2.1] hept-1- yl-methane sulfonic acid) and salts thereof, 1- (4-tert
  • Methoxycinnamic acid isopentyl ester, 4-methoxycinnamic acid 2-ethylhexyl ester, 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid and its sodium salt, 3- (4'-methylbenzylidene) -D, L-camphor, 3-benzylidene-camphor, 4-Isopropylbenzyl salicylate, 2,4,6-trianilino (p-carbo-2'-ethylhexyl-1'-oxi) -1, 3,5-triazine, 3-imidazol-4-yl-acrylic acid and its ethyl ester, polymers of the N- ⁇ (2 and 4) - [2-oxoborn-3-ylidenemethyl] benzyl ⁇ -acrylamide.
  • water-insoluble UV filters are those which dissolve in water at not more than 1% by weight, in particular not more than 0.1% by weight, at 20 ° C. Furthermore, these compounds should be soluble in the usual cosmetic oil components at room temperature to at least 0.1, in particular at least 1 wt .-%).
  • the use of water-insoluble UV filters may therefore be preferred according to the invention. According to a further embodiment of the invention, preference is given to those UV filters which have a cationic group, in particular a quaternary ammonium group.
  • UV filters have the general structure U - Q.
  • the structural part U stands for a UV-absorbing group.
  • This group can in principle be derived from the known UV filters which can be used in the cosmetics sector, in which a group, generally a hydrogen atom, of the UV filter is replaced by a cationic group Q, in particular having a quaternary amino function ,
  • Compounds from which the structural part U can be derived are, for example, substituted benzophenones, p-aminobenzoic acid esters,
  • Structural parts U which are derived from cinnamic acid amide or from N, N-dimethylaminobenzoic acid amide are preferred according to the invention.
  • the structural parts U can in principle be selected such that the absorption maximum of the UV filters can be in both the UVA (315-400 nm) and in the UVB (280-315 nm) or in the UVC ( ⁇ 280 nm) range. UV filters with an absorption maximum in the UVB range, in particular in the range from about 280 to about 300 nm, are particularly preferred.
  • the structural part U also as a function of structural part Q, is preferably selected so that the molar extinction coefficient of the UV filter at the absorption maximum is above 15,000, in particular above 20,000.
  • the structural part Q preferably contains, as a cationic group, a quaternary ammonium group.
  • This quaternary ammonium group can in principle be connected directly to the structural part U, so that the structural part U represents one of the four substituents of the positively charged nitrogen atom.
  • one of the four substituents on the positively charged nitrogen atom is a group, especially an alkylene group of 2 to 6 carbon atoms, which functions as a compound between the structural portion U and the positively charged nitrogen atom.
  • the group Q has the general structure - (CH 2 ) ⁇ -N + R 1 R 2 R 3 X " , in which x is an integer from 1 to 4, R 1 and R 2 independently of one another represent
  • x is preferably the number 3
  • R 1 and R 2 are each a methyl group and R 3 is either a methyl group or a saturated or unsaturated , linear or branched hydrocarbon chain having 8 to 22, in particular 10 to 18, carbon atoms.
  • Physiologically acceptable anions are, for example, inorganic anions such as halides, in particular chloride, bromide and fluoride, sulfate ions and phosphate ions and organic anions such as lactate, citrate, acetate, tartrate, methosulfate and tosylate.
  • inorganic anions such as halides, in particular chloride, bromide and fluoride, sulfate ions and phosphate ions and organic anions such as lactate, citrate, acetate, tartrate, methosulfate and tosylate.
  • UV filters with cationic groups are the commercially available compounds cinnamic acid-trimethylammonium chloride (lncroquat ® UV-283) and dodecyl tosylate (Escalol ® HP 610).
  • the teaching of the invention also includes the use of a combination of several UV filters.
  • the combination of at least one water-insoluble UV filter with at least one UV filter with a cationic group is preferred.
  • the UV filters (I) are usually contained in the agents according to the invention in amounts of 0.1-5% by weight, based on the total agent. Levels of 0.4-2.5 wt .-% are preferred.
  • compositions of the invention may further contain a 2-pyrrolidinone-5-carboxylic acid and its derivatives (J).
  • a 2-pyrrolidinone-5-carboxylic acid and its derivatives Preference is given to the sodium, potassium, calcium, magnesium or ammonium salts in which the ammonium ion carries, in addition to hydrogen, one to three C 1 - to C 4 -alkyl groups.
  • the sodium salt is most preferred.
  • the amounts used in the compositions according to the invention are preferably from 0.05 to 10% by weight, based on the total composition, particularly preferably from 0.1 to 5, and in particular from 0.1 to 3,% by weight.
  • compositions according to the invention contain penetration aids and / or swelling agents (M).
  • M penetration aids and / or swelling agents
  • M include, for example, urea and urea derivatives, guanidine and its derivatives, arginine and its derivatives, water glass, imidazole and its derivatives, histidine and its derivatives, benzyl alcohol, glycerol, glycol and glycol ethers, propylene glycol and propylene glycol ethers, for example propylene glycol monoethyl ether, carbonates, bicarbonates, Diols and triols, and in particular 1, 2-diols and 1, 3-diols such as 1, 2-propanediol, 1, 2-pentanediol, 1, 2-hexanediol, 1, 2-dodecanediol, 1, 3-propanediol, 1 , 6-hexanediol, 1, 5-pentanediol, 1, 4-
  • short-chain carboxylic acids may additionally support the active substance complex (A).
  • carboxylic acids which may be saturated or unsaturated and / or straight-chain or branched or cyclic and / or aromatic and / or heterocyclic and have a molecular weight of less than 750.
  • preference may be given to saturated or unsaturated straight-chain or branched carboxylic acids having a chain length of from 1 to 16 C atoms in the chain, very particular preference being given to those having a chain length of from 1 to 12 C atoms in the chain.
  • the short-chain carboxylic acids according to the invention may have one, two, three or more carboxy groups.
  • Preferred within the meaning of the invention are carboxylic acids having a plurality of carboxy groups, in particular di- and tricarboxylic acids.
  • the carboxy groups may be wholly or partly present as esters, acid anhydride, lactone, amide, imidic acid, lactam, lactim, dicarboximide, carbohydrazide, hydrazone, hydroxam, hydroxime, amidine, amidoxime, nitrile, phosphonic or phosphate ester.
  • the carboxylic acids used according to the invention may of course be substituted along the carbon chain or the ring skeleton.
  • the substituents of the carboxylic acids used according to the invention include, for example, C 1 -C 8 -alkyl, C 2 -C 8 -alkenyl, aryl, aralkyl and aralkenyl, hydroxymethyl, C 2 -C 8 -hydroxyalkyl, C 2 -C 8 -hydroxyalkenyl , Aminomethyl, C 2 -C 8 -aminoalkyl, cyano, formyl, oxo, thioxo, hydroxy, mercapto, amino, carboxy or imino groups.
  • Preferred substituents are C 1 -C 8 alkyl, hydroxymethyl, hydroxy, amino and carboxy groups.
  • substituents in the D position are hydroxyl, alkoxy and amino groups, where the amino function may optionally be further substituted by alkyl, aryl, aralkyl and / or alkenyl radicals.
  • preferred carboxylic acid derivatives are the phosphonic and phosphate esters.
  • the agents according to the invention may contain emulsifiers (F).
  • Emulsifiers effect at the phase interface the formation of water- or oil-stable adsorption layers, which protect the dispersed droplets against coalescence and thus stabilize the emulsion.
  • Emulsifiers are therefore constructed like surfactants from a hydrophobic and a hydrophilic part of the molecule. Hydrophilic emulsifiers preferably form O / W emulsions and hydrophobic emulsifiers preferably form W / O emulsions.
  • An emulsion is to be understood as meaning a droplet-like distribution (dispersion) of a liquid in another liquid under the expense of energy in order to create stabilizing phase interfaces by means of surfactants.
  • the selection of these emulsifying surfactants or emulsifiers depends on the substances to be dispersed and the respective outer phase and the fineness of the emulsion.
  • Emulsifiers which can be used according to the invention are, for example
  • Glucosides mixtures of alkyl (oligo) and fatty alcohols for example, the commercially available product ® Montanov 68,
  • Sterols are understood to mean a group of steroids which have a hydroxyl group on C-atom 3 of the steroid skeleton and are isolated both from animal tissue (zoosterols) and from vegetable fats (phytosterols). Examples of zoosterols are cholesterol and lanosterol. Examples of suitable phytosterols are ergosterol, stigmasterol and sitosterol. Mushrooms and yeasts are also used to isolate sterols, the so-called mycosterols.
  • glucose phospholipids e.g. as lecithins or phosphatidylcholines from e.g. Egg yolk or plant seeds (e.g., soybeans) are understood.
  • Fatty acid esters of sugars and sugar alcohols such as sorbitol
  • Polyglycerols and polyglycerol derivatives such as polyglycerol poly-12-hydroxystearate (commercial product Dehymuls ® PGPH),
  • Linear and branched fatty acids with 8 to 30 C atoms and their Na, K, ammonium, Ca, Mg and Zn salts.
  • the agents according to the invention preferably contain the emulsifiers in amounts of 0.1-25% by weight, in particular 0.5-15% by weight, based on the total agent.
  • compositions according to the invention may preferably contain at least one nonionogenic emulsifier having an HLB value of 8 to 18.
  • Nonionic emulsifiers having an HLB value of 10 to 15 may be particularly preferred according to the invention.
  • the anionic polymers (G2) are anionic polymers which have carboxylate and / or sulfonate groups.
  • anionic monomers from which such polymers may consist are acrylic acid, methacrylic acid, crotonic acid, maleic anhydride and 2-acrylamido-2-methylpropanesulfonic acid.
  • the acidic groups may be wholly or partly present as sodium, potassium, ammonium, mono- or triethanolammonium salt.
  • Preferred monomers are 2-acrylamido-2-methylpropanesulfonic acid and acrylic acid.
  • Anionic polymers which contain 2-acrylamido-2-methylpropanesulfonic acid as the sole or co-monomer can be found to be particularly effective, it being possible for the sulfonic acid group to be wholly or partly present as sodium, potassium, ammonium, mono- or triethanolammonium salt ,
  • the homopolymer of 2-acrylamido-2-methyl propane sulfonic acid which is available for example under the name Rheothik ® 11-80 is commercially.
  • copolymers of at least one anionic monomer and at least one nonionic monomer are preferable to use copolymers of at least one anionic monomer and at least one nonionic monomer.
  • anionic monomers reference is made to the substances listed above.
  • Preferred nonionic monomers are acrylamide, methacrylamide, acrylic esters, methacrylic esters, vinylpyrrolidone, vinyl ethers and vinyl esters.
  • Preferred anionic copolymers are acrylic acid-acrylamide copolymers and in particular polyacrylamide copolymers with sulfonic acid-containing monomers.
  • a particularly preferred anionic copolymer consists of 70 to 55 mol% of acrylamide and 30 to 45 mol% of 2-acrylamido-2-methylpropanesulfonic acid, wherein the sulfonic acid group is wholly or partly in the form of sodium, potassium, ammonium, mono- or triethanolammonium Salt is present.
  • This copolymer may also be crosslinked, with crosslinking agents preferably polyolefinically unsaturated compounds such as tetraallyloxyethane, allylsucrose, allylpentaerythritol and methylenebisacrylamide are used.
  • crosslinking agents preferably polyolefinically unsaturated compounds such as tetraallyloxyethane, allylsucrose, allylpentaerythritol and methylenebisacrylamide are used.
  • crosslinking agents preferably polyolefinically unsaturated compounds such as tetraallyloxyethane, allylsucrose, allylpentaerythritol and methylenebisacrylamide are used.
  • Such a polymer is contained in the commercial product Sepigel ® 305 from SEPPIC.
  • Simulgel ® 600 as a compound with isohexadecane and polysorbate-80 Natriumacryloyldimethyltaurat copolymers have proved to be particularly effective according to the invention.
  • preferred anionic homopolymers are uncrosslinked and crosslinked polyacrylic acids. Allyl ethers of pentaerythritol, sucrose and propylene may be preferred crosslinking agents. Such compounds are for example available under the trademark Carbopol ® commercially.
  • Copolymers of maleic anhydride and methyl vinyl ether, especially those with crosslinks, are also color-retaining polymers.
  • a 1, 9-decadiene crosslinked maleic acid-methyl vinyl ether copolymer is available under the name ® Stabileze QM.
  • the agents according to the invention may contain nonionic polymers (G4).
  • Suitable nonionic polymers are, for example:
  • Vinylpyrrolidone / vinyl ester copolymers as sold, for example, under the trademark Luviskol ® (BASF).
  • Luviskol ® VA 64 and Luviskol ® VA 73, each vinylpyrrolidone / vinyl acetate copolymers are also preferred nonionic polymers.
  • Cellulose ethers such as hydroxypropyl cellulose, hydroxyethyl cellulose and hydroxypropylcellulose Methylhy-, as sold for example under the trademark Culminal® ® and Benecel ® (AQUALON) and Natrosol ® grades (Hercules).
  • Starch and its derivatives in particular starch, such as Structure XL ® (National Starch), a multifunctional, salt-tolerant starch; shellac
  • Siloxanes These siloxanes can be both water-soluble and water-insoluble. Both volatile and nonvolatile siloxanes are suitable, nonvolatile siloxanes being understood as meaning those compounds whose boiling point is above 200 ° C. under normal pressure.
  • Preferred siloxanes are polydialkylsiloxanes, such as, for example, polydimethylsiloxane, polyalkylarylsiloxanes, such as, for example, polyphenylmethylsiloxane, ethoxylated polydialkylsiloxanes and polydialkylsiloxanes which contain amine and / or hydroxyl groups. Glycosidically substituted silicones.
  • the preparations comprise a plurality of, in particular two, different polymers of the same charge and / or in each case an ionic and an amphoteric and / or nonionic polymer.
  • the other polymers (G) are contained in the agents according to the invention preferably in amounts of 0.05 to 10 wt .-%, based on the total agent. Amounts of 0.1 to 5, in particular from 0.1 to 3 wt .-%, are particularly preferred.
  • compositions according to the invention have advantageous properties and also confer advantageous properties on the hair treated with them. Benefits have been observed especially in hair and scalp treatment.
  • hair treatment compositions according to the invention increase the elasticity of the hair treated with them and lead to an inner-structural strengthening of the hair fibers, which is e.g. reflected in higher melting temperatures in differential thermal analysis. By stimulating the energy metabolism in the hair follicles and / or their activation, the hair is vitalized and promoted hair growth.
  • compositions according to the invention cause an increase in the elasticity and, surprisingly, sebum-regulating effects.
  • the visual impression of "greasy" skin or hair is thus avoided or weakened.
  • Another object of the present invention is the use of hair treatment compositions according to the invention for
  • the object of the present invention is the use of mixtures of
  • Methyltriethanolammoniummethylsulfat-dialkylester- mixture (INCI name: Distearoylethyl Hydroxyethylmonium Methosulfate, Cetearyl Alcohol) (Henkel)
  • Gluadin ® W20 Wheat Protein hydrolyzate (at least 20% solids, INCI name: Aqua (Water), Hydrolyzed Wheat Protein, Sodium Benzoate, Phenoxyethanol, Methylparaben, Propylparaben) (Cognis) Salcare ® SC 96 about 50% active ingredient content; INCI name: Polyquaternium-37, Propylene Glycol Dicaprylate / Dicaprate, PPG-1 Trideceth-6 (CIBA)
  • Synthalen ® K polyacrylic acid (about 89% active ingredient content, INCI name: carbomer) (3V Sigma) Sepigel ® 305 about 45-49% solids; INCI name: polyacrylamide, Ci 3-14 isoparaffin, Laureth-7) (Seppic) Dehyquart ® F75 fatty alcohol Methyltriethanolammoniummethylsulfat-dialkylester- mixture (INCI name: Distearoylethyl Hydroxyethylmonium Methosulfate, Cetearyl Alcohol) (Henkel)
  • Luviskol ® K30 polyvinylpyrrolidone (INCI name: PVP) (BASF) Gafquat ® 755 dimethylaminoethyl methacrylate-vinylpyrrolidone copolymer, quaternized with diethyl sulfate (ca. 19% solids in water; INCI name: Polyquaternium-11) (ISP)
  • Salcare ® SC 96 about 50% active ingredient content; INCI name: Polyquaternium-37,

Abstract

Agents de traitement capillaire conférant des qualités avantageuses aux cheveux traités et protégeant la chevelure contre des agressions extérieures. Ces agents contiennent au moins une substance de soin cationique, 0,1 à 10% en poids d'un ou plusieurs constituants gras, 0,001 à 5% en poids de mélatonine (I) et/ou un de ses sels et/ou agomélatine (II) et/ou un de ses sels, ainsi qu'au moins 0,001 à 5% en poids d'un exhausteur de soin du groupe L-carnitine et/ou ses sels; panthénol; 2-furanone, en particulier pantolactone; taurine et/ou ses sels; des vitamines, en particulier niacinamide, biotine, acide pantothénique et tocophérol et/ou leurs dérivés; ubiquinone; ectoïne; allantoïne; des extraits de plantes, en particulier echinacea ou moringa; xanthine, en particulier caféine, théophylline et théobromine; des flavonoïdes, en particulier des flavonols; bisabolol; créatine.
PCT/EP2008/053226 2007-08-22 2008-03-18 Agents de traitement capillaire contenant une ou plusieurs substances de soin et mélatonine/agomélatine WO2009024359A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007039745A DE102007039745A1 (de) 2007-08-22 2007-08-22 Haarbehandlungsmittel mit Pflegestoff(en) und Melatonin/Agomelatin
DE102007039745.5 2007-08-22

Publications (1)

Publication Number Publication Date
WO2009024359A1 true WO2009024359A1 (fr) 2009-02-26

Family

ID=39595949

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/053226 WO2009024359A1 (fr) 2007-08-22 2008-03-18 Agents de traitement capillaire contenant une ou plusieurs substances de soin et mélatonine/agomélatine

Country Status (2)

Country Link
DE (1) DE102007039745A1 (fr)
WO (1) WO2009024359A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100633A1 (fr) * 2012-12-20 2014-06-26 Arch Chemicals, Inc. Compositions topiques comportant des fluides ioniques
WO2013075892A3 (fr) * 2011-11-23 2014-09-04 Henkel Ag & Co. Kgaa Produits de conditionnement capillaire

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010063584A1 (de) * 2010-12-20 2012-06-21 Henkel Ag & Co. Kgaa Kationische Styrol/Acrylat-Copolymere in Haarbehandlungsmitteln
DE102011082898A1 (de) * 2011-09-16 2013-03-21 Henkel Ag & Co. Kgaa Haarpflegemittel mit gesteigerten Pflegeleistungen
DE102012219587A1 (de) * 2012-10-25 2014-04-30 Henkel Ag & Co. Kgaa Klares Pflegespray mit gesteigerter Leistung
CN107205908B (zh) * 2015-01-30 2020-03-10 现代药品株式会社 稳定性得到改善的含褪黑激素的育发、养发或生发促进用组合物
BR112018010381B1 (pt) 2015-11-24 2021-08-17 L'oreal Composição para tratamento de cabelo, sistema para tratamento de cabelo, métodos para tratamento de cabelo e para alteração da cor do cabelo, e, kit de multicompartimentos para alteração da cor ou do formato do cabelo
US11135150B2 (en) 2016-11-21 2021-10-05 L'oreal Compositions and methods for improving the quality of chemically treated hair
US9974725B1 (en) 2017-05-24 2018-05-22 L'oreal Methods for treating chemically relaxed hair
EP4011355A1 (fr) 2017-12-29 2022-06-15 L'oreal Compositions pour modifier la couleur des cheveux
US11090249B2 (en) 2018-10-31 2021-08-17 L'oreal Hair treatment compositions, methods, and kits for treating hair
US11419809B2 (en) 2019-06-27 2022-08-23 L'oreal Hair treatment compositions and methods for treating hair
DE102019131415A1 (de) * 2019-11-21 2021-05-27 Lukas Karrer Kosmetische Pflege von ergrautem Haar und Wiederrückführung von ergrautem Haar zur ursprünglichen Haarfarbe

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194614A (en) * 1990-02-27 1993-03-16 Adir Et Compagnie Compounds having a naphthalene structure
US5939084A (en) * 1996-10-10 1999-08-17 Societe L'oreal S.A. Aqueous phase dermatological/cosmetic compositions comprising solubilized melatonin values
US6013279A (en) * 1994-12-08 2000-01-11 Klett-Loch; Lore Maria Combination preparation for stimulating the growth of hair and optionally the growth of skin and nails as well as for preventing or eliminating the loss of hair
WO2002069927A1 (fr) * 2001-03-05 2002-09-12 Asat Ag Applied Science & Technology Preparations de melatonine-vitamine-a
WO2007003307A1 (fr) * 2005-07-05 2007-01-11 Henkel Kommanditgesellschaft Auf Aktien Agents contenant de la l-carnitine, des derives de l-carnitine et au moins une autre substance

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5136093A (en) 1991-02-06 1992-08-04 Smith Ronald J Quaternized panthenol compounds and their use
DE4413686C2 (de) 1994-04-20 1996-10-24 Henkel Kgaa Kationische Zuckertenside, Verfahren zu ihrer Herstellung und deren Verwendung
DE19756454C1 (de) 1997-12-18 1999-06-17 Henkel Kgaa Verwendung von Glycerincarbonat

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194614A (en) * 1990-02-27 1993-03-16 Adir Et Compagnie Compounds having a naphthalene structure
US6013279A (en) * 1994-12-08 2000-01-11 Klett-Loch; Lore Maria Combination preparation for stimulating the growth of hair and optionally the growth of skin and nails as well as for preventing or eliminating the loss of hair
US5939084A (en) * 1996-10-10 1999-08-17 Societe L'oreal S.A. Aqueous phase dermatological/cosmetic compositions comprising solubilized melatonin values
WO2002069927A1 (fr) * 2001-03-05 2002-09-12 Asat Ag Applied Science & Technology Preparations de melatonine-vitamine-a
WO2007003307A1 (fr) * 2005-07-05 2007-01-11 Henkel Kommanditgesellschaft Auf Aktien Agents contenant de la l-carnitine, des derives de l-carnitine et au moins une autre substance

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013075892A3 (fr) * 2011-11-23 2014-09-04 Henkel Ag & Co. Kgaa Produits de conditionnement capillaire
WO2014100633A1 (fr) * 2012-12-20 2014-06-26 Arch Chemicals, Inc. Compositions topiques comportant des fluides ioniques

Also Published As

Publication number Publication date
DE102007039745A1 (de) 2009-02-26

Similar Documents

Publication Publication Date Title
WO2009024359A1 (fr) Agents de traitement capillaire contenant une ou plusieurs substances de soin et mélatonine/agomélatine
DE102008020044A1 (de) Pflegendes Haarbehandlungsverfahren
DE102010043074A1 (de) Wirkstoffkombination und Haarbehandlungsmittel gegen Schuppen III
DE102008045511A1 (de) Haarbehandlungsmittel mit niedrigdosierten Oligopeptiden
DE102009048299A1 (de) Haarbehandlungsmittel mit Tensid(en) und Proteolipid(en)
DE102007039519A1 (de) Kosmetische Mittel mit Chitosan und Silikonelastomeren
DE102008036075A1 (de) Pflegendes Haarreinigungsmittel mit Bioaktivstoffen
EP2164456B1 (fr) Produit de traitement capillaire avec oligopeptides
DE102010043075A1 (de) Wirkstoffkombination und Haarbehandlungsmittel gegen Schuppen I
WO2009024360A1 (fr) Agents de traitement capillaire contenant un ou plusieurs tensioactifs et mélatonine/agomélatine
DE102008022712A1 (de) Haarreinigungsmittel mit Frucht- und/oder Gemüsesaft
DE102010043076A1 (de) Wirkstoffkombination und Haarbehandlungsmittel gegen Schuppen II
DE102011087343A1 (de) Haarbehandlungsmittel mit 4-morpholinomethyl-substituierten Silikon(en)
DE102009027360A1 (de) Haarschutz-Kosmetikum I
EP2775998A2 (fr) Produits de soins capillaires
WO2009024361A1 (fr) Agents de traitement capillaire contenant un ou plusieurs alcools et de la mélatonine/agomélatine
WO2009074366A1 (fr) Produits pour le lavage des cheveux à action combinée détergente/soignante
DE102009044977A1 (de) Kosmetisches Mittel enthaltend Purin und/oder ein Purinderivat und Sclareol
WO2011000649A2 (fr) Produit cosmétique de protection capillaire ii
DE102010062662A1 (de) Wirkstoffkombination und Haarbehandlungsmittel
DE102008062771A1 (de) Kosmetische Mittel mit Edelholzextrakten
DE102012206948A1 (de) Haarbehandlungsmittel mit hydroxy-terminierten Organopolysiloxan(en) und Verdickungsmittel(n)
DE102012206949A1 (de) Haarbehandlungsmittel mit hydroxy-terminierten Organopolysiloxan(en) und Konditioniermittel(n)
DE102010043071A1 (de) Haarbehandlungsmittel mit 3-Methyl-1,3-Butandiol und Alkylpolyglycosid(en)
WO2009071355A1 (fr) Produits d'hygiène capillaire contenant une association de tensioactifs et d'épaississants

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08717958

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08717958

Country of ref document: EP

Kind code of ref document: A1